In relapsing-remitting multiple sclerosis, activation of the peripheral immune system can lead to focal inflammation within the CNS. Over the past three decades, therapeutic development has been ...

Antonella Favit-Van Pelt, MD, PhD, discusses the use of neuromodulation and neuroplasticity for addressing gait deficits in patients with multiple sclerosis.

A significant number of people lose their lives to multiple sclerosis each year, and many of these victims come from rural areas. However, the technology for early sclerosis diagnosis is not as ...

Multiple sclerosis (MS) is a chronic inflammatory disorder that is thought to impact about 2.3 million people around the world. This disorder is characterized by the loss of a protective neuronal ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that ...

Multiple sclerosis (MS) is a demyelinating disease that affects the central nervous system (CNS) and is characterized by the presence of CNS lesions. Volumetric measures of tissues, including lesions, ...